Collegium Pharmaceutical ... (COLL)
NASDAQ: COLL
· Real-Time Price · USD
38.32
-0.91 (-2.32%)
At close: Sep 05, 2025, 3:59 PM
38.32
0.00%
After-hours: Sep 05, 2025, 04:42 PM EDT
-2.32% (1D)
Bid | 36.63 |
Market Cap | 1.21B |
Revenue (ttm) | 707.01M |
Net Income (ttm) | 36.27M |
EPS (ttm) | 1.06 |
PE Ratio (ttm) | 36.15 |
Forward PE | 5.12 |
Analyst | Buy |
Ask | 40 |
Volume | 414,329 |
Avg. Volume (20D) | 416,168.5 |
Open | 39.23 |
Previous Close | 39.23 |
Day's Range | 38.18 - 39.55 |
52-Week Range | 23.23 - 42.29 |
Beta | 0.68 |
About COLL
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol COLL
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for COLL stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock ForecastsNext Earnings Release
Collegium Pharmaceutical Inc. is scheduled to release its earnings on
Nov 6, 2025,
during market hours.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
6 months ago
+2.22%
Collegium Pharmaceuticals shares are trading highe...
Unlock content with
Pro Subscription
6 months ago
+0.25%
Collegium Pharmaceuticals shares are trading higher after the company reported better-than-expected Q4 financial results.

4 weeks ago · seekingalpha.com
Collegium Pharmaceutical, Inc. (COLL) Q2 2025 Earnings Call TranscriptCollegium Pharmaceutical, Inc. (NASDAQ:COLL ) Q2 2025 Earnings Conference Call August 7, 2025 8:00 AM ET Company Participants Colleen Tupper - Executive VP & CFO Ian Karp - Corporate Participant Scott...

4 weeks ago · fool.com
Collegium (COLL) Q2 Revenue Jumps 29%Collegium (COLL) Q2 Revenue Jumps 29%

2 months ago · seekingalpha.com
Collegium Pharmaceutical: Stock Deserves A "Buy" Call On Undervaluation Of ADHD DrugCollegium is shifting focus from opioids to ADHD with Jornay PM, which is showing strong prescription growth and could become a blockbuster product. The company is undervalued relative to peers, with ...